|
1
|
Yadav D and Lowenfels AB: The epidemiology
of pancreatitis and pancreatic cancer. Gastroenterology.
144:1252–1261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heinemann V: Present and future treatment
of pancreatic cancer. Semin Oncol. 29(Suppl 9): 23–31. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hertel LW, Boder GB, Kroin JS, Rinzel SM,
Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor
activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer
Res. 50:4417–4422. 1990.PubMed/NCBI
|
|
5
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar
|
|
10
|
Singh S, Singh PP, Singh AG, Murad MH,
McWilliams RR and Chari ST: Anti-diabetic medications and risk of
pancreatic cancer in patients with diabetes mellitus: A systematic
review and meta-analysis. Am J Gastroenterol. 108:510–519; quiz
520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jalving M, Gietema JA, Lefrandt JD, de
Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: Taking away
the candy for cancer? Eur J Cancer. 46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morran DC, Wu J, Jamieson NB, Mrowinska A,
Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ, et al
Australian Pancreatic Cancer Genome Initiative (APGI): Targeting
mTOR dependency in pancreatic cancer. Gut. 63:1481–1489. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhong H, Chiles K, Feldser D, Laughner E,
Hanrahan C, Georgescu MM, Simons JW and Semenza GL: Modulation of
hypoxia-inducible factor 1alpha expression by the epidermal growth
factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human
prostate cancer cells: Implications for tumor angiogenesis and
therapeutics. Cancer Res. 60:1541–1545. 2000.PubMed/NCBI
|
|
15
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Büchler P, Reber HA, Lavey RS, Tomlinson
J, Büchler MW, Friess H and Hines OJ: Tumor hypoxia correlates with
metastatic tumor growth of pancreatic cancer in an orthotopic
murine model. J Surg Res. 120:295–303. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaupel P: The role of hypoxia-induced
factors in tumor progression. Oncologist. 9(Suppl 5): 10–17. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar :
|
|
19
|
Yoneyama H, Takizawa-Hashimoto A, Takeuchi
O, Watanabe Y, Atsuda K, Asanuma F, Yamada Y and Suzuki Y: Acquired
resistance to gemcitabine and cross-resistance in human pancreatic
cancer clones. Anticancer Drugs. 26:90–100. 2015. View Article : Google Scholar
|
|
20
|
Office of Laboratory Animal Welfare
(OLAW): Institutional Animal Care and Use Committee Guidebook. OLAW
National Institutes of Health; Bethesda, MD: 2002
|
|
21
|
Ovejera AA, Houchens DP and Barker AD:
Chemotherapy of human tumor xenografts in genetically athymic mice.
Ann Clin Lab Sci. 8:50–56. 1978.PubMed/NCBI
|
|
22
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sah RP, Nagpal SJ, Mukhopadhyay D and
Chari ST: New insights into pancreatic cancer-induced
paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 10:423–433.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cui Y and Andersen DK: Pancreatogenic
diabetes: Special considerations for management. Pancreatology.
11:279–294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ewald N, Kaufmann C, Raspe A, Kloer HU,
Bretzel RG and Hardt PD: Prevalence of diabetes mellitus secondary
to pancreatic diseases (type 3c). Diabetes Metab Res Rev.
28:338–342. 2012. View Article : Google Scholar
|
|
26
|
Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W,
Zhao G and Kip KE: Reduced risk of colorectal cancer with metformin
therapy in patients with type 2 diabetes: A meta-analysis. Diabetes
Care. 34:2323–2328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cerezo M, Tichet M, Abbe P, Ohanna M,
Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P,
Bertolotto C, et al: Metformin blocks melanoma invasion and
metastasis development in AMPK/p53-dependent manner. Mol Cancer
Ther. 12:1605–1615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim HG, Hien TT, Han EH, Hwang YP, Choi
JH, Kang KW, Kwon KI, Kim BH, Kim SK, Song GY, et al: Metformin
inhibits P-glycoprotein expression via the NF-κB pathway and CRE
transcriptional activity through AMPK activation. Br J Pharmacol.
162:1096–1108. 2011. View Article : Google Scholar :
|
|
29
|
Rozengurt E, Sinnett-Smith J and Kisfalvi
K: Crosstalk between insulin/insulin-like growth factor-1 receptors
and G protein-coupled receptor signaling systems: A novel target
for the antidiabetic drug metformin in pancreatic cancer. Clin
Cancer Res. 16:2505–2511. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sinnett-Smith J, Kisfalvi K, Kui R and
Rozengurt E: Metformin inhibition of mTORC1 activation, DNA
synthesis and proliferation in pancreatic cancer cells: Dependence
on glucose concentration and role of AMPK. Biochem Biophys Res
Commun. 430:352–357. 2013. View Article : Google Scholar :
|
|
31
|
Karnevi E, Said K, Andersson R and
Rosendahl AH: Metformin-mediated growth inhibition involves
suppression of the IGF-I receptor signalling pathway in human
pancreatic cancer cells. BMC Cancer. 13:2352013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith
J and Rozengurt E: Different patterns of Akt and ERK feedback
activation in response to rapamycin, active-site mTOR inhibitors
and metformin in pancreatic cancer cells. PLoS One. 8:e572892013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL
and Reddy SA: The rapamycin analog CCI-779 is a potent inhibitor of
pancreatic cancer cell proliferation. Biochem Biophys Res Commun.
331:295–302. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pham NA, Schwock J, Iakovlev V, Pond G,
Hedley DW and Tsao MS: Immunohistochemical analysis of changes in
signaling pathway activation downstream of growth factor receptors
in pancreatic duct cell carcinogenesis. BMC Cancer. 8:432008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ito D, Fujimoto K, Mori T, Kami K, Koizumi
M, Toyoda E, Kawaguchi Y and Doi R: In vivo antitumor effect of the
mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human
pancreatic cancer. Int J Cancer. 118:2337–2343. 2006. View Article : Google Scholar
|
|
37
|
Gingras AC, Raught B and Sonenberg N:
Regulation of translation initiation by FRAP/mTOR. Genes Dev.
15:807–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fingar DC, Richardson CJ, Tee AR, Cheatham
L, Tsou C and Blenis J: mTOR controls cell cycle progression
through its cell growth effectors S6K1 and 4E-BP1/eukaryotic
translation initiation factor 4E. Mol Cell Biol. 24:200–216. 2004.
View Article : Google Scholar :
|
|
39
|
Fingar DC, Salama S, Tsou C, Harlow E and
Blenis J: Mammalian cell size is controlled by mTOR and its
downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:1472–1487.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang Q, Jurisica I, Do T and Hedley DW:
Hypoxia predicts aggressive growth and spontaneous metastasis
formation from orthotopically grown primary xenografts of human
pancreatic cancer. Cancer Res. 71:3110–3120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Semenza GL, Agani F, Feldser D, Iyer N,
Kotch L, Laughner E and Yu A: Hypoxia, HIF-1, and the
pathophysiology of common human diseases. Adv Exp Med Biol.
475:123–130. 2000. View Article : Google Scholar : PubMed/NCBI
|
